Pozen Scores Win In Shareholder Suit Over Treximet
A federal court has dismissed a consolidated putative securities class action against Pozen Inc. over disclosures made while the pharmaceutical company was seeking approval from the U.S. Food and Drug Administration...To view the full article, register now.
Already a subscriber? Click here to view full article